Revenue Beat and Packed Calendar Lift ANAB After Earnings
AnaptysBio climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain.
/ 58 items
#XY Earnings Movers↓
Capricor Soars After Cantor Upgrade as FDA Path for Deramiocel Becomes Clearer
Analyst upgrade sends Capricor shares higher after company outlines BLA amendment path for deramiocel focused on upper-limb function.
Omeros Shares Surge as YARTEMLEA Sales Crush Expectations in Q2
First full quarter of YARTEMLEA delivers $28.5M net product sales and turns Omeros profitable on an adjusted basis in Q2 2026.
Mereo BioPharma Secures Major Option Deal for Alvelestat and Extends Cash Runway
Mereo BioPharma shares rose ~27% after a key option-and-license deal for alvelestat with Sentynl and an updated cash runway into late 2027.
HIMS Drops After Earnings as Margin Collapse Overshadows Strong Growth
Despite beating estimates and raising full-year outlook, HIMS stock dropped after investors focused on the bigger-than-expected loss and collapsing margins.
Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.